Rigel Pharmaceuticals, Inc. (RIGL)

Rigel Pharmaceuticals topped expectations on both the top and bottom line in the second fiscal quarter of 2026, reported August 4, 2026, even as results fell year over year. Revenue fell 22.6% to about $78.7 million (down from about $101.7 million a year ago), but still topped consensus at $78.7 million versus an estimate of $55.3 million, +42.4%. EPS of $0.88 topped the $0.09 estimate by $0.79, though it was down from $3.28 a year ago (down 73.2% year over year). Profitability remained high, with gross margin at roughly 89% alongside gross profit of about $70.2 million, while operating margin held near 30% with operating income of roughly $23.6 million. Net income declined 71.0% year over year to about $17.3 million (down from about $59.6 million a year ago). The company generated operating cash flow of about $30.7 million. Next-period consensus calls for EPS of $0.92 on revenue of $80.1 million.